Dose adjustment of carboplatin in patients on peritoneal dialysis

被引:4
作者
Guddati, Achuta K. [1 ]
Joy, Parijat S. [2 ]
Marak, Creticus P. [3 ]
机构
[1] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Internal Med, Boston, MA 02114 USA
[2] Univ Iowa, Dept Internal Med, Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA
[3] Tahlequah City Hosp, Div Pulm Med, Dept Med, Tahlequah, OK 74464 USA
关键词
Carboplatin; AUC; Dose; Peritoneal dialysis;
D O I
10.1007/s12032-014-0946-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The Calvert equation has been extensively used to determine the dosage of carboplatin. However, in patients on dialysis, it predicts the same dosage regardless of the frequency of dialysis. Clearance of carboplatin during hemodialysis has been studied to a lesser extent, but there have been very few studies which have investigated the clearance of carboplatin in patients on peritoneal dialysis. A mathematical formula is proposed here to predict the dose of carboplatin for a given AUC in patients on peritoneal dialysis. This formula takes into account the frequency of dialysis sessions and the time delay between carboplatin infusion and the initiation of dialysis. The formula predicts an approximately similar dosage of carboplatin as that of the Calvert formula in patients undergoing peritoneal dialysis four times per day if dialysis is initiated 12 h after infusion. The formula may help in guiding the adjustment of carboplatin dose in patients who receive a lesser number of dialysis sessions per day and in those patients whose dialysis is initiated at different times (0-24 h) after carboplatin infusion. It is suggested that usage of this formula will result in a better dosage of carboplatin to suit specific dialysis frequencies in specific patients and eventually may result in a better efficacy and toxicity profile.
引用
收藏
页数:4
相关论文
共 5 条
[1]   CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION [J].
CALVERT, AH ;
NEWELL, DR ;
GUMBRELL, LA ;
OREILLY, S ;
BURNELL, M ;
BOXALL, FE ;
SIDDIK, ZH ;
JUDSON, IR ;
GORE, ME ;
WILTSHAW, E .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) :1748-1756
[2]   ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends [J].
Grassmann, A ;
Gioberge, S ;
Moeller, S ;
Brown, G .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2005, 20 (12) :2587-2593
[3]   Dose adjustment of carboplatin in patients on hemodialysis [J].
Guddati, Achuta K. ;
Joy, Parijat S. ;
Marak, Creticus P. .
MEDICAL ONCOLOGY, 2014, 31 (03)
[4]   Continuous ambulatory peritoneal dialysis: pharmacokinetics and clinical outcome of paclitaxel and carboplatin treatment [J].
Heijns, Joan B. ;
van der Burg, Maria E. L. ;
van Gelder, Teun ;
Fieren, Marien W. J. A. ;
de Bruijn, Peter ;
van der Gaast, Ate ;
Loos, Walter J. .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (05) :841-847
[5]   Cancer in patients on dialysis for end-stage renal disease: an international collaborative study [J].
Maisonneuve, P ;
Agodoa, L ;
Gellert, R ;
Stewart, JH ;
Buccianti, G ;
Lowenfels, AB ;
Wolfe, RA ;
Jones, E ;
Disney, APS ;
Briggs, D ;
McCredie, M ;
Boyle, P .
LANCET, 1999, 354 (9173) :93-99